Therapy innovation for the treatment of pancreatic neuroendocrine tumors. - Wikidata - awgldk - TriplyDB

Therapy innovation for the treatment of pancreatic neuroendocrine tumors.

Therapy innovation for the treatment of pancreatic neuroendocrine tumors.

http://www.wikidata.org/entity/Q37988905

about

Pharmacotherapy of Zollinger-Ellison syndrome.Therapy of metastatic pancreatic neuroendocrine tumors (pNETs): recent insights and advances

P2860

Q36632665-B2A1F2F6-5149-428A-A0B1-4DA2B73BF533 Q37125550-81BA0903-39B5-4CD7-805D-852D0EBAC8CA

P2860

Therapy innovation for the treatment of pancreatic neuroendocrine tumors.

http://www.wikidata.org/entity/Q37988905

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Therapy innovation for the treatment of pancreatic neuroendocrine tumors.

@en

Therapy innovation for the treatment of pancreatic neuroendocrine tumors.

@nl

type

label

Therapy innovation for the treatment of pancreatic neuroendocrine tumors.

@en

Therapy innovation for the treatment of pancreatic neuroendocrine tumors.

@nl

prefLabel

Therapy innovation for the treatment of pancreatic neuroendocrine tumors.

@en

Therapy innovation for the treatment of pancreatic neuroendocrine tumors.

@nl

P1433

Q37988905-C67F4556-7083-468E-B524-FBABF3C220C0

P1476

Q37988905-E03CD42F-D6A8-4958-9FEA-099A3A987957

P2093

Q37988905-235B035B-4176-4A91-B5A4-70A838D330BB

Q37988905-70C93B50-9E89-441A-B99F-26FF303958D2

Q37988905-772A04F1-E11D-4B02-8AA6-7F1D863977F3

Q37988905-9C0B8BC5-D296-404F-9682-2BA5201DB7DC

Q37988905-9FA5BC5B-06EE-4EF5-8C27-EE4ABA568D22

Q37988905-BC9A652F-DBAD-4BB7-8998-F9951E1FABF4

Q37988905-F7C60FCE-DA1C-43A7-800D-E156CE33B10C

P2860

Q37988905-011895D4-07DB-4891-9E4A-D23954D615BE

Q37988905-03BF6B0B-DC49-4691-A177-8E825461FE9D

Q37988905-05A3C047-4A9F-4141-846F-C8F2E2FF183D

Q37988905-10EA1465-EAF7-4FB4-A1FA-0D5D95E3C8C4

Q37988905-13831D60-034F-405C-AC7F-B6365977EC16

Q37988905-183C5BC6-96E8-4D99-A56F-04ED6702C568

Q37988905-21A58101-A1AE-4598-A439-1DE832377C4D

Q37988905-24E4D296-FC90-4736-92EC-92D8A822383E

Q37988905-25CB3EE2-1F1F-4278-8E14-EC6DB38F4A44

Q37988905-27722D2C-8E5D-4774-8EE8-B8330C6E925D

P304

Q37988905-2144615C-4833-41AF-BFEB-E49F46D3BD39

P31

Q37988905-1BFB916B-C4E9-4CB1-83F2-C6C8A9EAAD38

P356

Q37988905-1D4B35FD-CCFB-4D24-9BFE-68113D85E003

P407

Q37988905-68A2A77B-75AF-4981-B8FE-F345EE836323

P478

Q37988905-6C7C1FFD-8F94-4337-992C-B597D0680D0E

P577

Q37988905-FB8F55A7-12D8-416D-8FC6-584A737EF807

P698

Q37988905-10EA376A-899B-4C7A-B963-198D523C9CB9

P356

14728222.2012.665880

P1433

Expert Opinion on Therapeutic Targets

P1476

Therapy innovation for the treatment of pancreatic neuroendocrine tumors.

@en

P2093

Carlo Molino

http://www.w3.org/2001/XMLSchema#string

Ferdinando Riccardi

http://www.w3.org/2001/XMLSchema#string

Francesca Ambrosio

http://www.w3.org/2001/XMLSchema#string

Generoso Uomo

http://www.w3.org/2001/XMLSchema#string

Giacomo Cartenì

http://www.w3.org/2001/XMLSchema#string

Lucia Festino

http://www.w3.org/2001/XMLSchema#string

Mimma Rizzo

http://www.w3.org/2001/XMLSchema#string

P2860

Pericytes promote endothelial cell survival through induction of autocrine VEGF-A signaling and Bcl-w expression

Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis

From targets to treatments: a review of molecular targets in pancreatic neuroendocrine tumors

The pathologic classification of neuroendocrine tumors: a review of nomenclature, grading, and staging systems

Gastrointestinal neuroendocrine tumors: pancreatic endocrine tumors

Current knowledge on diagnosis and staging of neuroendocrine tumors

Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors

Tumorigenesis and the angiogenic switch

Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer.

Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors.

P304

S91-102

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/14728222.2012.665880

http://www.w3.org/2001/XMLSchema#string

P407

P478

16 Suppl 2

http://www.w3.org/2001/XMLSchema#string

P577

2012-02-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22372544

http://www.w3.org/2001/XMLSchema#string